---
schema_version: "secwatch.filing_event.v1"
accession: "0001999480-25-000035"
form_type: "8-K"
ticker: "ANRO"
cik: "0001999480"
company_name: "Alto Neuroscience, Inc."
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T10:49:23.518595+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Alto Neuroscience Q1 net loss $15.2M; cash $161.3M; key trial readouts on track

## Summary
- Net loss of $15.2M for Q1 2025 vs $13.4M in Q1 2024; R&D expense flat at $10.0M.
- Cash, cash equivalents and restricted cash of $161.3M as of March 31, 2025, expected to fund operations into 2028.
- ALTO-203 Phase 2 POC MDD trial topline data expected in Q2 2025; ALTO-101 Phase 2 CIAS data in H2 2025.
- ALTO-300 Phase 2b MDD trial data expected mid-2026; ALTO-100 Phase 2b BPD trial data H2 2026.
- At annual meeting, stockholders reelected Husseini Manji as Class I director and ratified Deloitte as auditor.

## SEC filing metadata
- accession: 0001999480-25-000035
- form_type: 8-K
- ticker: ANRO
- cik: 0001999480
- company_name: Alto Neuroscience, Inc.
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1999480/000199948025000035/0001999480-25-000035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1999480/000199948025000035/alto-20250513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001999480-25-000035
- JSON: https://secwatch.observer/filing/0001999480-25-000035.json
- Plain text: https://secwatch.observer/filing/0001999480-25-000035.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.